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Correlation between mean 
platelet volume and total 
risk of cardiovascular 
disease
ABSTRACT
Introduction. The association between mean platelet volume (MPV) and single cardiovascular disease (CVD) risk factors 
has previously been tested. The aim of our study was to evaluate the association between MPV and total risk of CVD. 
Materials and Methods. In 216 consecutive outpatients referred for  a cardiology assessment because of multiple CVD risk 
factors, total CVD risk was estimated according to the Framingham Risk Score (FRS) as  low (<10%), intermediate (11-19%), 
and high (>20%). Additionally, FRS was adjusted for triglycerides (TG), body mass index (BMI) and a family history of CVD, 
important CVD risk factors which are not included in the FRS equation. Also, CVD risk was estimated according to terciles 
of MPV (<8.3, 8.3-9.1, >9.1 fL, respectively). Correlation between high sensitivity C-reactive protein (hs-CRP) and FRS was 
used as confirmation that our study hypothesis was properly set.
Results. MPV did not correlate with individual CVD risk factors or with FRS, either before, or after adjustment for additional 
CVD risk factors. Significant correlation between MPV and total CV risk was observed only in the adjusted high FRS group; 
namely, for persons in tercile 3, CVD risk was doubled (OR 2.2; 95% CI 1.05-4.64; P =0.038). In comparison, there was a 
strong linear correlation between hs-CRP and unadjusted (r=0.203, P=0.004) and adjusted (r=0.383, P<0.001) FRS.
Conclusion. Correlation between MPV and high total CVD risk suggests increased platelet activity primarily as a consequ-
ence and sign of atherosclerotic vascular damage. Linear correlation between hs-CRP with FRS confirms inflammation as 
an important mechanism of atherogenesis.
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Introduction
Major cardiovascular and cerebrovas-
cular events (e.g. myocardial infarction 
and stroke) can occur in individuals wit-
hout known pre-existing cardiovascular 
(CV) disease. Because CV diseases 
are more likely to occur in patients with 
certain risk factors, prevention of such 
events, including the accurate identifi-
cation of those at increased risk, has 
been developed using traditional CV 
risk factors (e.g. cigarette smoking, 
blood pressure, cholesterol, diabetes 
mellitus, obesity, family history of CV 
diseases). The coexistence of multiple 
CV risk factors multiplies the risk of 
adverse CV events. (1) Following this, 
total CV risk assessment using models 
that include multiple CV risk factors is 
recommended. One of these models 
is the Framingham Risk Score (FRS), a 
simplified prediction tool developed to 
enable clinicians to estimate CV risk in 
individuals, often considered the refe-
rence standard. (2) It includes age, 
gender, smoking, blood pressure, total 
and HDL-cholesterol values, and dia-
betes, and estimates the 10 year risk of 
CV events by stratifying individuals into 
the three risk categories: low, interme-
diate, and high. (2)
In order to better assess CV risk and 
to clarify the pathogenesis of atherot-
hrombosis, some biochemical markers 
are stressed. One of them is mean pla-
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telet volume (MPV), a potential mar-
ker of platelet reactivity, which is one 
of the major culprit mechanisms in 
atherothrombotic events. Large plate-
lets - characterized by a higher MPV 
- contain more dense granules and are 
metabolically and enzymatically more 
active than small platelets; therefore 
these platelets have higher thrombotic 
potential. Elevated values of MPV are 
associated with CV diseases, and also 
predict a poor outcome following acute 
coronary events or coronary interven-
tions. (3)
Several reports have demonstrated an 
association between MPV and traditio-
nal CV risk factors, such as hypertensi-
on, impaired fasting glucose, diabetes, 
hypercholesterolemia and obesity, sug-
gesting a possible mechanism in incre-
asing CV risk. (4-8) Based on these 
proven associations between MPV and 
single CV risk factors, in light of reco-
mmendations for total CV risk asses-
sment, (1) we assessed the association 
between MPV and total CV risk. 
Materials and Methods
Subjects
In this study we enrolled 216 consecu-
tive subjects [146 (65.74%) males], all 
older than 18 years of age (median age 
65 (26-87) years), without a history of 
clinically apparent CV diseases, that 
had been admitted to the Cardiology 
Department at the University Hospital 
of Split due to multiple CV risk factors. 
Recent research has shown that rosu-
vastatin and losartan can interfere with 
MPV so patients who used them were 
exluded from our study to eliminate 
possible errors. Exclusion criteria con-
sisted of a previous diagnosis of CV 
diseases (coronary artery disease, his-
tory of myocardial infarction or stroke, 
chronic heart failure), thyroid disease, 
renal or hepatic dysfunction, hema-
tological disease, cancer, thrombo-
cytopenia, autoimmune disease, sys-
temic inflammatory conditions, preg-
nancy, use of estrogen therapy (oral 
contraceptives or hormone replace-
ment therapy) or serotonin reuptake 
inhibitor drug use. 
The study was conducted according to 
the principles of the Helsinki Declara-
tion. The local Ethics Committee gave 
approval for this study. All patients 
agreed to participate voluntarily in the 
study after a detailed explanation of 
study objectives. All participants pro-
vided written informed consent after 
detailed explanation of study objec-
tives.
Collection of patient data
Trained research assistants filled out 
the questionnaire on demographic cha-
racteristics (age, sex, height and wei-
ght), the presence of traditional CV risk 
factors (arterial hypertension, diabetes, 
hypercholesterolemia, hypertriglyceri-
demia, cigarette smoking, family history 
of CV diseases), and medication used 
before admission. 
The presence of CV risk factors was 
defined as following: (1) diabetes 
mellitus - fasting blood glucose > 6.9 
mmol/L or non-fasting glucose level 
> 11 mmol/L, or use of antidiabetic 
medication. The subjects were identi-
fied as either presently suffering from 
diabetes or not; (2) arterial hypertensi-
on - systolic blood pressure >140 mm 
Hg, diastolic blood pressure >90 mm 
Hg, or previous use of antihypertensive 
drugs; (3) hypercholesterolemia – total 
cholesterol (TC) >4.5 mmol/L, LDL-
cholesterol (LDL-C) >2.5 mmol/L, or 
previous use of lipid-lowering therapy; 
(4) hypertriglyceridemia – triglycerides 
(TG) >1.8 mmol/L; (5) overweight - 
body mass index (BMI: weight/height2) 
> 25 kg/m2; (6) cigarette smoking was 
categorized as non smoking or ever 
smoking; (7) family history of CV disea-
ses included a history of sudden death, 
myocardial infarction, angina pecto-
ris or coronary revascularization in a 
first relative before the age of 55 years 
(men) or 65 years (women).
Collection and processing of diagno-
stic blood specimen
Blood samples were collected in the 
morning after a 20-min rest following a 
fasting period of 12 hours for the mea-
surement of TC, LDL-C, HDL-choleste-
rol (HDL-C), TG, and serum glucose. 
Plasma concentrations of glucose, TG, 
TC and HDL-C (after selective precipi-
tation with Immuno AG, Vienna, Austria) 
were measured by standard enzyma-
tic methods on an Olympus AU-640 
(Olympus, Tokyo, Japan). LDL-C was 
calculated using the Friedwald equa-
tion. If TG concentration was above 3 
mmol/L, HDL-C and LDL-C were mea-
sured by direct immunoinhibition met-
hod (Olympus Diagnostica, Lismee-
han, Ireland) and homogeneous assay 
(Randox Laboratories, Crumlin, United 
Kingdom), respectively. 
MPV was measured within 30 minu-
tes of sampling by Bechman Counter 
(USA) in a blood sample collected in 
citrate (1:4 v/v) in order to avoid plate-
let swelling induced by EDTA. Normal 
range of MPV in our laboratory ranged 
from 6-10.8 fL.
Assessment of individual’s CV disease 
risk level
Eight risk factors (age, sex, systolic and 
diastolic blood pressure, cholesterol 
and HDL-C levels, smoking, diabetes) 
were used to calculate an individual’s 
risk level of future development of CV 
diseases based on the FRS. Among 
these factors, age, blood pressure, cho-
lesterol and HDL-C levels were proce-
ssed according to their values and sex, 
smoking and diabetes were processed 
depending on whether it was positive 
or negative. Using these risk factors, 
the 10-year predicted risk of developing 
manifest CV disease was calculated for 
each case. In accordance with the FRS, 
the study population was then cate-
gorized as low (<10%), intermediate 
(11-19%), and high (>20%) risk. After 
that, in order to better estimate total CV 
risk, FRS was adjusted for TG, BMI and 
family history of CV diseases, traditional 
CV risk factors that are not included in 
the FRS equation.
High sensitivity C-reactive protein (hs-
CRP) as a control 
Hs-CRP, widely accepted as an inde-
pendent predictor of CV diseases, 
significantly correlates with calculated 
10-year FRS. (9) Therefore, we tested 
the correlation between hs-CRP and 
FRS as a confirmation that our study 
hypothesis was properly set.
Hs-CRP determination was performed 
with high sensitivity immunoturbidime-
tric assay (Cobas Integra 700, Roche, 
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Mannheim, Germany) with a detection 
limit of 0.25 mg/L, at the time of admi-
ssion and in a blind fashion. 
Statistical analysis 
Calculation of differences between 
baseline characteristics is presented 
as a means and standard deviation 
(M±SD) or percentage frequencies. 
Normally distributed values were com-
pared with Student’s tests, and skewed 
continuous variables by non-paramet-
ric rank sum tests. Chi-square tests or 
Fisher’s exact test were used for cate-
gorical variables. Pearson’s correlation 
was used to evaluate the association 
between MPV and serum values for 
single CV risk factors (age, sex, serum 
glucose, TC, HDL-C, LDL-C, systolic 
and diastolic blood pressure, BMI, 
smoking). The same test was used in 
assessment of the correlation between 
MPV and total CV risk expressed as 
FRS before and after adjusting for mul-
tiple potential confounders such as TG, 
BMI and a family history of CV disease. 










Demographic parameters and CV risk factors
FRS (%) 23.8±11.9 13±7.2 28.4±14.3 58.6±12.8 <0.001
Male (%) 65.74 7.7 24.6 67.6 <0.001
Age (years; M ± SD ) 65±9.7 56.78±12.06 63.59±8.71 68.3±8.24 <0.001
BMI (kg/m2; M ± SD ) 28.7±3.7 26.6±4.06 27.26±3.61 28.7±3.57 0.004
Overweight and obese (%) 82.2 10.3 25.3          64.4 <0.001
Arterial hypertension (%) 72.6 9.7 24.5 65.8 <0.001
Systolic BP (mm Hg, M ± SD) 138.5±19.3 123.04±12.12 131.72±16.04 145.21±19.11 <0.001
Diastolic BP (mm Hg, M ± SD) 82.9±11 79.11±9.53 80.59±10.68 84.94±11.04 0.005
Diabetes mellitus (%) 27.8 1.7 16.7 49.81 <0.001
Hypercholesterolemia (%) 27 13. 9 27.8 91.63 <0.001
Hypertriglyceridemia (%) 50.2 0 24.7 75.3 <0.001
Cigarette smoking (%) 13.4 10.3 20.7 69 <0.001
Family history of CVD (%) 14.8 8.4 11.2 26.3  0.07
Laboratory parameters (M ± SD)
Glucose (mmol/L) 6.7±4.5 5.47±0.68 6.15±1.73 7.32±5.69 0.067
Total cholesterol (mmol/L) 5±1.3 4.43±1 4.9±1.21 5.25±1.06 0.004
LDL-cholesterol (mmol/L) 2.8±0.97 2.42±0.9 2.78±0.96 3.2±1.06 0.001
HDL-cholesterol (mmol/L) 1.36±0.4 1.51±0.36 1.5±0.47 1.25±0.32 0.001
Triglycerides (mmol/L) 1.8±1.8 1.1±0.34 1.55±2.95 2.15±2.2 0.005
hs-CRP (mg/L) 2.46±2.9 1.7±1.72 2.4±2.95 3.3±4.08 0.064
MPV (fL) 8.77±1.03 8.69±1.18 8.78±1.14 8.84±1.07 0.79
Medications before admission (% of pts.)
Acetylsalicylic acid 57.9 15.2 26.4 58.4 0.473
Beta blockers 69 12.7 26.7  60.7 0.632
Calcium channel blockers 16.7  11.1 16.7 72.2 0.167
ACE inhibitors 47.22 4.9  31.4 63.7 0.003
Statins 54.2  16.2 32.5 51.3 0.052
BMI, body mass index; BP, blood pressure; FRS, Framingham Risk Score; CVD, cerebrovascular disease; hs-CRP, high sensitivity C-reactive 
protein; MPV, mean platelet volume.




Body Mass Index -0.03 0.692
Systolic blood pressure 0.08 0.261
Diastolic blood pressure 0.09 0.175
Total cholesterol -0.01 0.424
Triglycerides -0.07 0.353
HDL cholesterol 0.1 0.156
Fasting plasma glucose 0.01 0.926
Current smoking -0.05 0.429
High sensitivity C-reactive protein 0.01 0.936
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The ANOVA one way analysis was used 
to test the difference in the FRS among 
terciles of MPV (tercile 1, <8.3 fL; tercile 
2, 8.3-9.1 fL; and tercile 3, >9,1 fL) fol-
lowed by  multiple comparisons with the 
Bonferroni correction. Thereafter, an 
analysis of covariance was performed 
with the above-listed confounders as 
covariates. A multiple logistic regres-
sion analysis was performed to deter-
mine the odds ratio (OR) of high-risk 
for CV disease in each tertile of MPV, 
before and after adjusting for TG, BMI, 
and family history of CV disease. All 
statistical tests were two-sided and a 
P-value of less than 0.05 was consid-
ered to be significant. 
All analyses were performed with the 
Statistica 10 software package (Stat-
Soft. Inc.,Tulsa, USA). 
Results
The baseline characteristics of the study 
population by FRS are presented in table 
1. The mean FRS in the study subjects 
was 23.8±11.9%; 29 (13%) of the sub-
jects were in the low risk (FRS <10%), 59 
(27%) were in the intermediate risk (FRS 
11-19%), and 128 (60%) were in the high 
risk (FRS >20%) group. 
The median age of the whole study 
population was 65 (26-87) years. The 
most commonly represented risk fac-
tors were overweight (82.2%), hyperten-
sion (72.6%) and hypertriglyceridemia 
(50.2%), followed by diabetes (27.8%), 
hypercholesterolemia (27%), family his-
tory for CV diseases (14.8%) and smok-
ing (13.4%). 
The frequency and values of all CV risk 
factors were significantly increased 
from lower to higher FRS group (table 
1). Both, MPV (P =0.79) and hs-CRP 
(P =0.064) values showed a non-
significant increase according to FRS 
category.
A significantly higher percentage of 
high-risk patients used CV medications 
(table 1). However, a difference was 
only observed in relation to the use of 
ACE-inhibitors (P=0.003). The differ-
ence in statins use was on the border of 
statistical significance (P =0.052).
Pearson’s correlation coefficients of 
MPV with several clinical parameters 
are shown in table 2. There was no 
significant correlation between MPV 
and individual CV risk factors. A bor-
derline, but not statistically significant 
correlation was observed between MPV 
and systolic blood pressure (r=0.078, 
P =0.261), diastolic blood pressure 
(r=0.094, P =0.175) and HDL-C 
(r=0.099, P =0.156). There was no sig-
nificant correlation between MPV and 
FRS (r=0.008, P =0.914). Furthermore, 
the correlation remained insignificant 
after adjusting for TG, BMI, and family 
history of CV disease (partial r=-0.059, 
P =0.397). Also, there was no signifi-
cant correlation between MPV and hs-
CRP (r=0.006, P =0.936).
There was a strong linear correla-
tion between hs-CRP and FRS before 
(r=0.203, P =0.004) and after adjusting 
for TG, BMI, and a family history of CV 
disease (r=0.383, P <0.001) (figure 
2).
Although the FRS in the tercile 2 of MPV 
was slightly higher than in the tercile 1 
and tercile 3, a statistically significant 
difference in unadjusted FRS values 
among MPV terciles was  not revealed 
(F=0.93, df=2, P =0.398) (figure 1, 
left panel). Correlation between FRS, 
Figure 1. Correlation between MPV and unadjusted and adjusted (adjusted for 
triglicerydes, obesity, and family history of cardiovascular disease) 
Framingham Risk Score (FRS).
Figure 2. Correlation between C-reactive protein and unadjusted and adjusted 
(adjusted for triglicerydes, obesity, and family history of cardiovas-
cular disease) Framingham Risk Score (FRS).
 53www.signavitae.com
according to terciles of MPV after 
adjusting for TG, BMI, and family history 
for CV diseases, is presented in figure 
1, right panel. Paradoxically, the FRS 
values were slightly decreased from 
MPV tercile 1 to MPV tercile 3. How-
ever, even after adjusting differences 
in FRS, correlation among MPV terciles 
were remained nonsignificant (F=1.16, 
df=2, P =0.316). 
The ORs of high-risk for CV disease 
(FRS >20%) in each tercile of MPV 
are presented in figure 3. Insignificant 
increases in unadjusted risk in each ter-
cile were noted; OR for tercile 2 (regard-
ing to the referent tercile 1) was 1.56 
(95% CI 0.79-3.06; P =0.19, and for 
tercile 3 was 1.73 (95% CI 0.88-3.42; P 
=0.11). Significant correlation between 
MPV and total CV risk was observed 
only in the adjusted high FRS group. 
Namely, after adjusting for TG, BMI, 
and a family history of CV disease, for 
persons in tercile 3, a doubled increase 
in CV risk (OR 2.2; 95% CI 1.05-4.64; P 
=0.038) was noted in comparison to 
tercile 1.
Discussion
Although the association between MPV 
and single traditional CV risk factors 
has previously been tested, to the best 
of our knowledge this study is the first 
to investigate the association between 
MPV and total individual CV risk. Con-
trary to most previous studies, (3-8) our 
study did not demonstrate an associa-
tion between MPV and single traditional 
CV risk factors. Moreover, correlation 
between MPV and total CV risk became 
significant only in patients with high 
FRS after adjusting for TG, BMI and 
family history for CV diseases, impor-
tant traditional risk factors which are not 
included in the FRS equation. 
According to current theories, athe-
rosclerosis is a chronic inflammatory 
process in which many cell types 
participate in its initiation and progre-
ssion. (10) Traditional CV risk factors 
damage endothelial cells and initiate 
atherosclerotic processes for which 
progression is an important interaction 
between activated endothelial cells, 
platelets, monocytes, macrophages, 
and smooth muscle cells. It is likely that 
platelets represent an important linkage 
between inflammation, atherogenesis 
and thrombosis. (10-12)
Increased platelet activity is associa-
ted with increased platelet volume. (3) 
Large platelets that contain more dense 
granules are metabolically and enzy-
matically more active than small plate-
lets and containing more prothrombotic 
material. (3,12,13) They show greater 
aggregability in response to ADP and 
decreased inhibition of aggregation by 
prostacyclin in vitro. Large platelets are 
denser and contain more ?-granules 
which can release prothrombotic 
substances. (3, 12, 13) Based on these 
observations, elevated MPV is accep-
ted as an indicator of platelet activation 
and indirectly, as a marker of increased 
CV risk.
A close relationship between MPV and 
CV risk factors, such as hypertensi-
on, impaired fasting glucose, diabetes, 
hypercholesterolemia and obesity has 
been demonstrated in several studi-
es. (3-8) In hypertension and diabe-
tes, MPV is higher in patients with the 
progression of basic disease and the 
presence of target organ damage. 
(14,15) In patients with diabetes, MPV 
positively correlates with microvascular 
complications, and severity of angi-
ographically proven coronary artery 
disease. (14) In hypertensive patients, 
MPV levels strongly correlate with seve-
rity of subclinical target organ dama-
ge, including carotid atherosclerosis, 
left ventricular hypertrophy and renal 
dysfunction. (15)
Hypercholesterolemia, hypertriglyce-
ridemia and abdominal obesity are 
directly associated with elevated MPV. 
(16) Moreover, when hypertriglyceri-
demia and abdominal obesity combi-
ne with elevated blood pressure and 
hyperglycemia, MPV elevation beco-
mes more expressed and dependent 
on metabolic status. (17)
Observations that MPV positively corre-
lates with single traditional risk factors 
and that the coexistence of multiple 
CV risk factors multiplies the risk of 
adverse CV events, formed the basis 
of our hypothesis that MPV positively 
correlates with total CV risk. Following 
this, we performed total CV risk asse-
ssment using the FRS, a simplified 
prediction tool developed to enable 
clinicians to estimate an individual’s CV 
risk, and often considered the referen-
ce standard. (2) Unexpectedly, we did 
not reveal a linear association between 
MPV and FRS. The correlation between 
MPV and FRS became significant only 
in people with a high FRS after adju-
sting for TG, BMI, and family history 
of CV disease. A possible explanation 
is that being overweight and having 
hypertriglyceridemia, important factors 
for metabolic syndrome (16-18), were 
more frequently observed in patients 
in the high FRS group. Therefore, our 
results stress the importance of these 
FRS, Framingham Risk Score; MPV, mean platelet volume; OR, odds ratio.
Figure 3. Increasing risk for high-risk FRS (>20%) group based on MPV; 
adjusted for triglyceridemia, body mass index and family history of 
cardiovascular disease.
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factors in atherogenesis and also in CV 
risk prediction. Namely, the FRS does 
not account for metabolic syndrome 
which is strongly associated with athe-
rogenesis, and often underestimates 
total CV risk in patients with these risk 
factors. (16-18)
Correlation between MPV and high total 
CV risk, observed in our study, sugge-
sts the possibility that increased MPV 
reflects advanced vascular damage. 
Even in asymptomatic patients with 
multiple CV risk factors. 
Namely, damaged vascular cells rele-
ase substances that activate platelets, 
and increase thrombogenesis and the 
potential for development of adver-
se CV events. (12,13) In this light, it 
is possible to interpret the results of 
studies that have shown associations 
between increased MPV with target 
organ damage in patients with hyper-
tension and diabetes, (14,15) and also 
in patients with acute coronary syndro-
me. (19,20) As in acute coronary syn-
drome, in which rupture of the fibrous 
cap allows contact of the platelets with 
the highly thrombogenic necrotic core, 
(19,20) vascular damage, caused by 
multiple CV risk factors, enables con-
tact between platelets and thromboge-
nic substances even in  asymptomatic 
patients. In both cases, the result is 
platelet activation. Therefore, increased 
platelet activity primarily appears as a 
consequence, not a cause of vascular 
damage. 
Previous studies also stress autonomic 
imbalances - increased sympathetic or 
decreased parasympathetic nervous 
system activity - as an important factor 
in the progression of atherosclerotic 
diseases, and development of their 
complications. (21) Moreover, it has 
been reported that lower heart rate vari-
ability (HRV) - which represents a domi-
nation of sympathetic activity – is signi-
ficantly associated with individual CV 
risk factors (22,23) and higher total CV 
risk estimated by FRS. (24) The spleen 
contains approximately one-third of all 
the body’s platelets. (25) These pla-
telets are relatively larger and hemo-
statically more active than platelets in 
the systemic circulation, and can be 
released into the systemic circulation 
by stimulation of alpha-adrenoceptors. 
(25) Therefore, it could be speculated 
that the correlation between MPV and 
high CV risk, observed in our patients, 
is a consequence of sympathetic pre-
domination and increased release of 
the larger, hemostatically more active 
platelets from the spleen to the syste-
mic circulation. 
We revealed a significant positive linear 
correlation between FRS values with 
hs-CRP, which is widely accepted as an 
independent predictor of CV diseases. 
(9,11) In agreement with our data, a 
positive correlation between hs-CRP 
with calculated 10-year FRS has been 
previously confirmed. (9,11) There-
fore, a positive association between 
hs-CRP with unadjusted and adjusted 
calculated 10-year FRS, confirms the 
meaningfulness of our hypothesis and 
properly conducted research. Also, 
this observation suggests hs-CRP is 
a significantly better marker of CV risk 
than MPV, and supports the observa-
tion that inflammation has an active 
role in the initiation and progression of 
atherosclerotic disease. (10)
Study limitations.
We acknowledge the following limi-
tations in this study. This was a cro-
ss-sectional rather than a prospective 
study. Also, the blood sample from 
each participant in the study was taken 
only once.  Therefore, we were unable 
to investigate how temporary changes 
in levels of serum parameters might 
impact the FRS and its relation to MPV; 
also, for the same reasons, we were 
unable to identify a causal relationship 
between MPV and FRS. 
It is possible that rosuvastatin and 
losartan exhibit antithrombotic proper-
ties independently to changes in the 
lipid profile or blood pressure. (26,27) 
Therefore, it is important that not a sin-
gle  patient included in our study used 
these drugs. There are no data about 
the potential effect of the other anti-
hypertensive and hypolipidemic drugs 
on MPV values. Moreover, all of these 
drugs have been used in previous 
studies in which positive associations 
between MPV and single CV risk factors 
were observed.   
Also, we eliminated potential technical 
factors which could have affected our 
results. EDTA, used for anticoagulation 
of whole blood prior to automated cell 
counting, may increase MPV due to 
platelet swelling. (28,29) However, it 
has been confirmed that MPV can be 
measured accurately by using EDTA 
and citrate if the analysis is performed 
within 1 h of sampling. (28,29) Also, 
it has been shown that changes in 
MPV, which reflect platelet sphering 
and swelling, were greatest between 30 
and 60 min in blood stored at ambient 
temperature. Because, in our study, 
blood samples were stored at 4°C and 
measurements were performed within 
30 min after collecting, using the same 
device, we are confident in the validity 
of our laboratory measurements. 
Finally, study subjects consisted of 
patients with a high CV risk referred 
to us for cardiology assessment for 
multiple CV risk factors; therefore selec-
tion was potentially biased. However, 
a significant positive (unadjusted and 
adjusted) association between hs-CRP 
with calculated 10-year FRS is confir-
mation that our results were properly 
taken and processed.  
Conclusion
Linear correlations between hs-CRP 
with FRS values confirm inflammation 
as an important mechanism in the initia-
tion and progression of atherogenesis. 
Correlation of MPV with high total CV 
risk suggests increased platelet activity 
primarily as a reflection of advanced 
atherosclerosis, and possible vascular 
damage, even in asymptomatic pati-
ents.   
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